BEIJING, July 8, 2015 /PRNewswire/ -- Sinovac Biotech Ltd.
(NASDAQ:SVA), a leading provider of biopharmaceutical products in
China, today announced that it
will hold its 2015 Annual Meeting of Shareholders on Tuesday, August 11, 2015 at 9:00 a.m. Beijing Time. The meeting will be held
at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC. All shareholders of record as of
June 30, 2015 will be eligible to
vote and are invited to attend.
The primary agenda of the meeting is to approve the re-election
of Weidong Yin, Yuk Lam Lo, Simon
Anderson, Kenneth Lee and
Meng Mei as the Company's directors
until the next annual meeting of shareholders and or until their
successors are duly elected; approve the audited consolidated
financial statements of the Company for the financial year ended
December 31, 2014 together with the
Report of Independent Registered Public Accounting Firm thereon and
the notes thereto; approve the appointment of Ernst &Young Hua
Ming LLP as the independent auditor of the Company for the fiscal
year ending December 31, 2015 and to
authorize the directors of the Company to fix such independent
auditor's remuneration.
Sinovac's 2014 annual report and proxy statements, including the
Notice of the 2015 Annual General Meeting, are available on the
Company's website: http://www.sinovac.com/?optionid=751.
Shareholders of the Company may receive a hard copy of 20-F free
of charge upon request. Such request can be made by sending an
e-mail to ir@sinovac.com, along with complete contact details and a
mailing address.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. Sinovac
has filed a new drug application with the China Food & Drug
Administration for its proprietary enterovirus 71 vaccine, having
been proven effective in preventing hand, foot and mouth disease in
infants and children during its Phase III clinical trial. The
Company is currently developing a number of new products including
a Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines in
China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to Mexico,
Mongolia, Nepal, and the
Philippines, and was recently granted a license to
commercialize its hepatitis A vaccine in Chile. For more information, please visit the
Company's website at www.Sinovac.com.
Contact
Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sinovac-schedules-2015-annual-meeting-of-shareholders-300110187.html
SOURCE Sinovac Biotech Ltd.